The FDA declined to approve one of biotech’s most closely watched cancer drugs
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
This is a brief. The reporting belongs to MarketWatch — read the complete story, with full context and credits, at the source.
Read the full story at MarketWatch ↗marketwatch.com
More from the Business desk
Just in
How to use options to bet against Big Tech, while keeping risk in check
Just in

Is Jensen Huang Plotting a Comeback?
Just in

Current price of oil as of November 16, 2026
Just in
Anthropic’s IPO is forcing investors to assess uninsurable risks they’ve never encountered before
